An Open-Label, Phase 1/1b Study of ORIC-944 as a Single Agent or in Combination With an Androgen Receptor Pathway Inhibitor in Patients With Metastatic Prostate Cancer

Summary

The purpose of this study is to establish the safety and preliminary antitumor activity of ORIC-944 as a single agent and in combinations with ARPIs in patients with metastatic prostate cancer.

Description

Eligibility

Age range

18+ years

Sex

Male

Healthy volunteers

No

Interventions

• Drug
  ORIC-944

  Oral, once daily, continuous

• Drug
  Abiraterone acetate (Zytiga®) 250 mg or 500 mg tablets

  Oral, 1000 mg once daily, continuous

• Drug
  Apalutamide (Erleada™) 60 mg or 240 mg tablets

  Oral, 240 mg once daily, continuous

• Drug
  Darolutamide (Nubeqa®) 300 mg tablets

  Oral, 600 mg twice daily, continuous

• Drug
  Enzalutamide (Xtandi®) 40 mg capsules or 40 mg and 80 mg tablets

  Oral, 160 mg once daily, continuous

Locations (27)